Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724410 | 0.89 | TLR7 (0.49) | TLR7ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1724376 | 0.84 | TLR7 (0.57) | TLR7ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1724102 | 0.79 | ADORA2B (0.45) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL18133294 | 0.76 | ADORA2B (0.46) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL7435440 | 0.76 | HPGD (0.57) | BRD4 | |
| SCHEMBL15064429 | 0.73 | ADORA2B (0.54) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1724705 | 0.72 | ADORA2B (0.58) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL18133300 | 0.72 | ADORA2B (0.42) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL1724557 | 0.70 | ADORA2B (0.46) | TLR7ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL806853 | 0.70 | ADORA2B (0.41) | ADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2024-09-19 | — | — | US | claimed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | claimed |
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | claimed |
| CN-111801099-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2020-10-20 | — | — | CN | claimed |
| US-20200316077-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2020-10-08 | — | — | US | claimed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | claimed |
| EP-2405917-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | Advinus Therapeutics Private Limited (IN) | 2012-01-18 | — | — | EP | claimed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | claimed |
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2024-09-19 | — | — | US | disclosed |
| CN-118001282-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-3727391-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | Impetis Biosciences Ltd. (IN) | 2020-10-28 | — | — | EP | disclosed |
| CN-111801099-A | Pharmaceutical composition for cancer treatment | 因佩蒂斯生物科学有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20200316077-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | IMPETIS BIOSCIENCES LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316077-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | ADORA2B, ADORA2A, ADORA3 | TLR7 1971/4885ADORA3 3/4885ADORA1 8/4885 |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | TLR7 270/4885ADORA3 3/4885ADORA1 2/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | TLR7 258/4885ADORA3 3/4885ADORA1 2/4885 |
| US-20240307402-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER | ADORA2B, ADORA2A, ADORA3 | TLR7 1971/4885ADORA3 3/4885ADORA1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.